Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P98066

UPID:
TSG6_HUMAN

ALTERNATIVE NAMES:
Hyaluronate-binding protein; TNF-stimulated gene 6 protein; Tumor necrosis factor alpha-induced protein 6

ALTERNATIVE UPACC:
P98066; Q53TI7; Q8WWI9

BACKGROUND:
Tumor necrosis factor alpha-induced protein 6, with alternative names Hyaluronate-binding protein and TNF-stimulated gene 6 protein, is a major regulator of the extracellular matrix. It facilitates the assembly of hyaluronan-rich matrices, essential for various cellular functions including macrophage extravasation and osteogenesis. By altering hyaluronan binding and modulating extracellular matrix components, it plays a significant role in cellular signaling and immune response.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted role of Tumor necrosis factor alpha-induced protein 6 in extracellular matrix organization and immune response modulation could lead to innovative therapeutic approaches. Its critical functions in tissue remodeling and immune regulation make it a promising candidate for drug discovery efforts aimed at treating related pathological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.